Lilly’s Solanezumab Slows Down Alzheimer’s Progression
Solanezumab, an experimental Eli Lilly medication for Alzheimer's disease, slowed the rate of cognitive decline and memory loss by approximately 30% among patients in early stages of the disease. Eli Lilly says the results of its latest clinical trial provides initial evidence that solanezumab may have an impact on the course of the disease...Does Reality Blend With Fiction When Making Decisions In Video Games? Rare Gene Deletion Tied To Psychiatric Disease And Obesity
